Industry news
Sellas Life Sciences to acquire Galena Therapeutics.
Sellas Life Sciences will acquire Galena Therapeutics assuring Sellas of a NASDAQ listing and a way forward to fund galinpepimut-S which is due to enter Phase III trials for AML and Mesothelioma.